Danaher Acquires Masimo for $9.9B, Reshaping Patient Monitoring

IRVINE, Calif. – February 17, 2026 – In a blockbuster move set to reshape the global medical technology landscape, science and technology conglomerate Danaher Corporation announced it will acquire patient monitoring innovator Masimo Corporation in a $9.9 billion all-cash deal. The definitive agreement, unanimously approved by both companies' boards, values Masimo at $180.00 per share, representing a nearly 40% premium over its recent trading price.

The acquisition marks a significant consolidation in the MedTech sector, bringing Masimo's industry-leading non-invasive monitoring technologies under the umbrella of Danaher's vast life sciences and diagnostics empire. Masimo will become a standalone business unit and brand within Danaher’s Diagnostics segment, a structure intended to preserve its identity while leveraging Danaher's global scale.

Danaher's Strategic Expansion into Acute Care

For Danaher, the acquisition is a calculated strategic maneuver to bolster its diagnostics portfolio and aggressively expand its footprint in the acute care market. While some analysts were surprised by the move, expecting Danaher to focus on its core life sciences business, the logic behind the purchase reveals a long-term vision for comprehensive patient care.

The deal creates powerful synergies by combining Masimo’s expertise in non-invasive pulse oximetry with Danaher’s existing Radiometer business, which specializes in invasive blood gas analysis. This integration allows Danaher to offer a complete suite of solutions for measuring blood health, covering the two most critical methods used in hospitals. Furthermore, the acquisition provides Danaher a crucial entry point into the rapidly growing telehealth and home monitoring markets, leveraging Masimo’s Root platform and wearable technologies. This aligns with the broader industry shift towards a “hospital-to-home” care continuum, enabling patient monitoring from the operating room all the way to a patient's residence.

At the heart of Danaher's strategy is its famed Danaher Business System (DBS), a proprietary set of tools for continuous improvement and operational excellence. Danaher has a long and successful history of applying DBS to its acquisitions—which include major players like Beckman Coulter, Cepheid, and Cytiva—to accelerate growth, control costs, and boost margins. The company projects that applying DBS to Masimo will yield over $125 million in annual cost synergies and more than $50 million in revenue synergies by the fifth year post-acquisition.

“We look forward to joining Danaher and continuing our growth and momentum as the global leader in patient monitoring,” said Katie Szyman, Chief Executive Officer of Masimo, in a statement. “Danaher shares our commitment to investing in talent and innovation and will be an ideal fit to help power the next chapter of Masimo.”

A Lucrative Exit After a Turbulent Period

The $9.9 billion price tag offers a significant windfall for Masimo shareholders, providing a definitive and premium value for their investment. The acquisition comes after a challenging period for the Irvine-based company, which saw its stock decline by 27% in the year leading up to the announcement and trade near 52-week lows.

Masimo had recently been embroiled in a high-profile patent infringement battle with Apple and faced pressure from activist investor Politan Capital Management, which led a successful campaign to reshape the company’s board. In a strategic realignment preceding the deal, Masimo had also divested its consumer audio division, Sound United. The acquisition by Danaher provides a stable and value-maximizing path forward, concluding a period of uncertainty.

Michelle Brennan, Chairman of Masimo’s Board of Directors, framed the deal as the culmination of an exhaustive strategic review. “This transaction represents a unique opportunity to deliver certain and premium value for Masimo’s shareholders, enhance outcomes for customers and patients, and provide compelling career growth paths for our employees across the world,” Brennan stated. “The Board evaluated a broad range of opportunities over the past several months... Ultimately, it became evident that this transaction with Danaher was the most value-enhancing path for Masimo and all its stakeholders.”

Market Reactions and the Road Ahead

The market’s reaction to the news was swift and decisive. Masimo’s stock (MASI) surged over 34% in morning trading, closing in on the $180 offer price. Conversely, Danaher’s stock (DHR) saw a modest dip of around 3-5%, a typical reaction as investors digest the financial implications of a large-scale acquisition.

Analysts noted that while the move into patient monitoring was somewhat unexpected, the financial rationale is sound. Masimo brings a strong, recurring revenue stream and significant market share—holding 23.1% of the U.S. pulse oximetry systems market in 2025—which aligns perfectly with Danaher's strategy of acquiring market leaders with potential for margin improvement.

The transaction is expected to close in the second half of 2026, pending customary closing conditions, including shareholder approval and the receipt of required regulatory approvals. While antitrust reviews are standard for a deal of this magnitude, some observers believe the complementary nature of the two businesses—one focused on non-invasive and the other on invasive technologies—may smooth the path to approval.

Once completed, the integration of Masimo into Danaher will be closely watched by competitors like Medtronic, Philips, and GE HealthCare. The combined entity is poised to become a dominant force in the global patient monitoring market, which is projected to grow from $48.5 billion in 2024 to over $71 billion by 2029. The successful fusion of Masimo's pioneering innovation with Danaher's operational prowess could set a new standard for technology-driven patient care for years to come.